France
Lys Therapeutics is a pioneering biotechnology company founded in 2021 with headquarters in France. The company's slogan, "First-in-class biotherapies against neurological diseases," encapsulates its primary focus on targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation to revolutionize the treatment of patients with neurodegenerative or neurovascular diseases.
In the pathophysiology of neurological diseases such as stroke, multiple sclerosis, and Parkinson's disease, Lys Therapeutics identifies the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) as a significant factor leading to BBB dysfunction, neuroinflammation, and neurodegeneration.
The company's lead drug candidate, LYS241, is a first-in-class monoclonal antibody designed to counteract these pathological mechanisms without interfering with the physiological function of NMDAr. This unique mechanism of action allows LYS241 to restore tight junctions, endothelial cell functionality, and BBB integrity, thereby protecting the brain from neuroinflammatory and neurodegenerative cascades.
The latest investment in Lys Therapeutics came in the form of non-equity assistance from Normandie Incubation on 15 May 2023, signaling validation and support for the company's innovative approach to combatting debilitating neurological disorders. With its promising pathway and innovative drug candidate, Lys Therapeutics represents an exciting prospect in the biotechnology, health care, and life sciences industries.
